• Iana H Haralambieva, Inna G Ovsyannikova, V Shane Pankratz, Richard B Kennedy, Robert M Jacobson, and Gregory A Poland.
• Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
• Expert Rev Vaccines. 2013 Jan 1; 12 (1): 57-70.

AbstractThe live-attenuated measles vaccine is effective, but measles outbreaks still occur in vaccinated populations. This warrants elucidation of the determinants of measles vaccine-induced protective immunity. Interindividual variability in markers of measles vaccine-induced immunity, including neutralizing antibody levels, is regulated in part by host genetic factor variations. This review summarizes recent advances in our understanding of measles vaccine immunogenetics relative to the perspective of developing better measles vaccines. Important genetic regulators of measles vaccine-induced immunity, such as HLA class I and HLA class II genotypes, single nucleotide polymorphisms in cytokine/cytokine receptor genes (IL12B, IL12RB1, IL2, IL10) and the cell surface measles virus receptor CD46 gene, have been identified and independently replicated. New technologies present many opportunities for identification of novel genetic signatures and genetic architectures. These findings help explain a variety of immune response-related phenotypes and promote a new paradigm of 'vaccinomics' for novel vaccine development.

20 keywords...

hide…